Considering the importance of ADRB1 and ADRB2 and their ligands in tumor progression in BCa and in BMD homeostasis, a treatment option for both targets is management with beta blockers (BBs), which are competitive inhibitors of ADRBs. Here, ADRB2 is linked to neoplasm.